NCT02240589View on ClinicalTrials.gov

Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Traumatic Brain Injury
Interventions
DRUG

Memantine

Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.

DRUG

Placebo

Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.

Trial Locations (1)

46202

Indiana University Health Facilities, Indianapolis

All Listed Sponsors
lead

Indiana University

OTHER

NCT02240589 - Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury | Biotech Hunter | Biotech Hunter